Novo’s Ozempic Pill Fails to Slow Alzheimer’s in Studies
A pill version of Novo Nordisk’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of trials. Naomi Kresge reports on Bloomberg Television (Source: Bloomberg)
By Bloomberg Markets · Bloomberg Markets
A pill version of Novo Nordisk’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of trials. Naomi Kresge reports on Bloomberg Television (Source: Bloomberg)